Benzodiazepines May Modify Ketamine Antidepressant Response, but the Evidence Was Heterogeneous

A possible reduction in antidepressant benefit is different from a demonstrated change in every acute ketamine effect.

What the supplied research shows

A 2021 systematic review examined pharmacodynamic interactions between ketamine and psychiatric medications. Across twenty-four included studies covering several drug classes, benzodiazepines repeatedly appeared to reduce the duration or magnitude of ketamine’s antidepressant response. The review also considered mood stabilizers and antipsychotics, with findings varying by medicine, population and endpoint.

What it cannot establish

The authors characterized the evidence as low quality because studies were small and used different participants, regimens and outcomes. Associations involving concurrent benzodiazepines may also reflect differences in underlying anxiety or illness. The review does not establish that every co-exposed patient loses benefit or provide a universal adjustment rule.

Forensic interpretation and case review

In expert interpretation, identify whether the question concerns mood response over days, immediate dissociation, sedation, memory or breathing. A result for one endpoint cannot be transferred automatically to another. Establish the benzodiazepine dose and timing, baseline illness and outcome assessment. This historical review offers a signal requiring careful qualification, rather than proof of treatment failure from a medication list alone or a basis for abrupt changes in prescribed therapy.

Source and related reading

Source: supplied full-text paper, PMC8538895. Research findings are paraphrased; the case-review discussion is an interpretation of that evidence.

Related: A Mixed Midazolam–Propofol Comparison Cannot Identify Midazolam’s Independent Mortality Effect.